{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:40:07Z","timestamp":1750005607652,"version":"3.41.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Limited data exist regarding how medications for pediatric use can be developed to minimize medication errors. The integrase inhibitor raltegravir was developed for use in neonates (\u22652\u2009kg). Anticipating that neonatal administration would be performed primarily by mothers with varying degrees of health literacy, a health literate, patient-focused, iterative process was conducted to update\/redesign the raltegravir granules for oral suspension pediatric kit and instructions for use (IFU) for neonatal use to be ready for regulatory submission.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Prototypes of an updated\/redesigned raltegravir IFU were systematically assessed through multi-stage, iterative testing and evaluation involving untrained lay individuals with varying levels of health literacy, healthcare professionals and health literacy experts.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>This iterative process resulted in numerous refinements to the IFU and kit, including wording, layout, presentation, colored syringes and additional instructional steps. The revised raltegravir pediatric kit and IFU (to include neonatal dosing) were approved by the US Food and Drug Administration in 2017 and the European Union in 2018. No reported medication errors related to IFU utilization had been reported as of March 2021, reflecting &gt;3 years of commercial use worldwide.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This patient-focused process produced health literate instructions for preparing and administering an antiretroviral for neonatal use with complex dosing requirements. Testing demonstrated that lay users with a range of health literacy levels were able to accurately mix, measure and administer the product. This process demonstrates how a neonatal medication can be optimized for use through collaboration between the infectious disease expert community and a manufacturer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003334","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T15:11:09Z","timestamp":1635174669000},"page":"51-56","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for Use"],"prefix":"10.1097","volume":"41","author":[{"given":"Alexander","family":"Mills","sequence":"first","affiliation":[{"name":"Devices and Combination Product Technology, Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Myers","sequence":"additional","affiliation":[{"name":"Health Equity, Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey","family":"Raudenbush","sequence":"additional","affiliation":[{"name":"CSRM, Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Vossen","sequence":"additional","affiliation":[{"name":"Devices and Combination Product Technology, Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hedy","family":"Teppler","sequence":"additional","affiliation":[{"name":"Clinical Research, Infectious Disease, Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanna R.","family":"Miteva","sequence":"additional","affiliation":[{"name":"Clinical Safety and Risk Management, Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Seeley","sequence":"additional","affiliation":[{"name":"Packaging Commercialization and Manufacturing Technology, Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Homony","sequence":"additional","affiliation":[{"name":"Clinical Sciences and Study Management (CSSM), Merck & Co., Inc., Kenilworth, New Jersey."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter L.","family":"Straus","sequence":"additional","affiliation":[{"name":"CSRM, Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,10,21]]},"reference":[{"key":"R2-20250615","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.3390\/ijms20112688","article-title":"Making medicines baby size: the challenges in bridging the formulation gap in neonatal medicine.","volume":"20","author":"O\u2019Brien","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R3-20250615","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/17512433.2018.1393331","article-title":"Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations.","volume":"11","author":"Clarke","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R5-20250615","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jpeds.2019.08.017","article-title":"Parent dosing tool use, beliefs, and access: a health literacy perspective.","volume":"215","author":"Williams","year":"2019","journal-title":"J Pediatr"},{"key":"R6-20250615","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/archdischild-2016-311877","article-title":"Medication errors by caregivers at home in neonates discharged from the neonatal intensive care unit.","volume":"102","author":"Solanki","year":"2017","journal-title":"Arch Dis Child"},{"key":"R7-20250615","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/QAD.0000000000000197","article-title":"Health literacy predicts pediatric dosing accuracy for liquid zidovudine.","volume":"28","author":"Howard","year":"2014","journal-title":"AIDS"},{"key":"R8-20250615","first-page":"e205","article-title":"Racial disparities in HIV antiretroviral medication management are mediated by health literacy.","volume":"2","author":"Waldrop-Valverde","year":"2018","journal-title":"Health Lit Res Pract"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/0956462417738679","article-title":"Health literacy and current CD4 cell count in a multiethnic U.S. sample of adults living with HIV infection.","volume":"29","author":"Walker","year":"2018","journal-title":"Int J STD AIDS"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1037\/a0032694","article-title":"A pandemic of the poor: social disadvantage and the U.S. HIV epidemic.","volume":"68","author":"Pellowski","year":"2013","journal-title":"Am Psychol"},{"key":"R14-20250615","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/QAI.0000000000002294","article-title":"Raltegravir (RAL) in neonates: dosing, pharmacokinetics (PK), and safety in HIV-1-exposed neonates at risk of infection (IMPAACT P1110).","volume":"84","author":"Clarke","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R18-20250615","doi-asserted-by":"crossref","first-page":"e20163237","DOI":"10.1542\/peds.2016-3237","article-title":"Pictograms, units and dosing tools, and parent medication errors: a randomized study.","volume":"140","author":"Yin","year":"2017","journal-title":"Pediatrics"},{"key":"R21-20250615","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/jamia\/ocv079","article-title":"Sometimes more is more: iterative participatory design of infographics for engagement of community members with varying levels of health literacy.","volume":"23","author":"Arcia","year":"2016","journal-title":"J Am Med Inform Assoc"},{"key":"R22-20250615","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/INF.0000000000002539","article-title":"Acceptability and feasibility of using raltegravir oral granules for the treatment of neonates in a low-resource setting.","volume":"39","author":"Archary","year":"2020","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:01:56Z","timestamp":1750003316000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,21]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003334","relation":{},"ISSN":["0891-3668"],"issn-type":[{"type":"print","value":"0891-3668"}],"subject":[],"published":{"date-parts":[[2021,10,21]]}}}